(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $4.10
発行日: 14 2月 2024 @ 23:30
リターン: -13.66%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: -0.93 %
Live Chart Being Loaded With Signals
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors...
Stats | |
---|---|
本日の出来高 | 402 127 |
平均出来高 | 979 955 |
時価総額 | 78.65M |
EPS | $0 ( 2024-03-27 ) |
次の収益日 | ( $-0.440 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.850 |
ATR14 | $0.0120 (0.34%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-03 | Brady Stephen R | Buy | 250 000 | Employee Stock Option (right to buy) |
2024-01-03 | Whiting Samuel | Buy | 100 000 | Employee Stock Option (right to buy) |
2024-01-03 | Trojanowski Justin | Buy | 26 500 | Employee Stock Option (right to buy) |
2024-01-03 | Maestas Nicholas | Buy | 40 000 | Employee Stock Option (right to buy) |
2023-10-11 | Brady Stephen R | Buy | 725 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
99.69 |
Last 85 transactions |
Buy: 12 322 880 | Sell: 50 340 |
ボリューム 相関
Tempest Therapeutics, 相関 - 通貨/商品
Tempest Therapeutics, 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-381 000 (0.00 %) |
EPS: | $-1.910 |
FY | 2023 |
収益: | $0 |
総利益: | $-381 000 (0.00 %) |
EPS: | $-1.910 |
FY | 2022 |
収益: | $0 |
総利益: | $-1.81M (0.00 %) |
EPS: | $-3.18 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-4.27 |
Financial Reports:
No articles found.
Tempest Therapeutics,
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。